Study details
Enrolling now
A Phase 1 Trial to Test a New Drug
TIXiMED, Inc.
NCT IDNCT06800729ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
35
Study length
about 4 months
Ages
18–70
Locations
1 site in CA
About this study
This trial is testing the safety, tolerability, and how your body processes TIX100 in healthy adults. Participants will receive either a placebo or TIX100 orally for 120 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Placebo
- 2.Take TIX100, an orally available inhibitor of thioredoxin-interacting protein
PhasePhase 1
Routeoral
Primary goalNumber of participants with treatment-related adverse events as assessed by CTCAE v5.0
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low15%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug routes
oral
Endpoints
Primary: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0